The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Adaptimmune Therapeutics plc(NASDAQ:ADAP) 
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to ide...
Website: http://www.adaptimmune.com
Full Time Employees: 420
Sector: Healthcare
Industry: Biotechnology
Adaptimmune Therapeutics plc Days Payable Outstanding ttm (DPO)
Adaptimmune Therapeutics plc Days Receivable Outstanding ttm (DSO)
Adaptimmune Therapeutics plc Op Cashflow Per Share ttm
Adaptimmune Therapeutics plc Free Cashflow Per Share ttm
Adaptimmune Therapeutics plc Cash Per Share ttm
Adaptimmune Therapeutics plc P/S ratio ttm
Adaptimmune Therapeutics plc (GAAP) P/E ratio ttm
Adaptimmune Therapeutics plc P/B ratio ttm
No extra charts and metrics for this ticker.